Rapid test for canine visceral leishmaniasis using lipophosphoglycan (TR-LVC-LPG)

Problem

Visceral leishmaniasis (VL) is considered one of the most neglected diseases in the world, affecting humans and other mammals. Dogs are the main domestic link of visceral leishmaniasis, and the main source of infection. Currently, there is great difficulty in diagnosing asymptomatic dogs, which makes it difficult to control the disease. The currently available test detects only 60% of infected dogs that do not show clinical manifestations.

Solution

The technology is about the development of the TR-LVC-LPG Kit, a "point of care" method developed from a non-protein antigen, lipophosphoglycan. The method has a sensitivity of 91.7%; 98.5% specificity; and accuracy of 99.7%. In this way, it is capable of properly distinguishing sera from sick infected dogs from those infected and clinically healthy. The test also showed low cross-reactivity when samples from dogs infected with other infectious agents were tested.

Differential

No refrigeration required	High sensitivity and specificity	No cross-reaction

Development stage

| 1 Basic Research | 2 Applied Research | 3 Concept Proof | 4 Laboratory scale test | 5 Pilot scale test | 6 Test prototype demonstrated in relevant environment | 7 Demonstration in operational environment | 8 Validated and qualified product | 9 Production and commercialization |

CONCEPT   PROTOTYPE   INDUSTRIALIZATION   PRODUCTION AND COMMERCIALIZATION

What we are searching for

Technology licensing agreement

WANT MORE INFORMATION? CONTACT US!

Inventors

Rodrigo Pedro Pinto Soares

Intellectual Property

Type
Invention Patent

Description
Patent application filed in Brazil, Europe and India.

ACCESS PATENT DOCUMENT

GESTEC

SISTEMA
GESTEC-NIT

Use your phone camera to scan
the QR Code:

Campus Fiocruz Maré - Av. Brasil, 4036 - Maré, Rio de Janeiro - RJ

CEP: 21040-361

portfolio@fiocruz.br

+55 (21) 3282-9080